Serina Therapeutics Inc (SER) Actualités

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Serina Therapeutics Announces Sale of UniverXome Subsidiary

- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15...

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form 8-K - Current report

Form 8-K - Current report

Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that...

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...